Update on new GPCode

On 26th January, we intercepted a new variant of GPCode,

This program, like its predecessors, encrypts users’ files. The author of the program demands payment for decrypting the files.

The new variant of GPCode was widely spammed throughout the Russian segement of the Internet. In spite of our warnings not to open attachments to email if you don’t know the sender, we’ve received a large number of reports from infected users.

Yesterday we added decryption for encrypted files to our antivirus databases. However, GPCode uses a number of encryption keys. It may be that some users’ data has been encrypted by keys which we haven’t seen yet. These users therefore won’t be able to use our antivirus to restore their data. We’d therefore urge anyone who’s been hit by this new version of GPCode to contact us.

In conclusion, as we’ve said many times before: sending money to the author(s) of these programs simply provides motivation to create another variant. Don’t ever send money to a cyber criminal. Send your infected files to us instead.

Update on new GPCode

Your email address will not be published. Required fields are marked *



Operation TunnelSnake

A newly discovered rootkit that we dub ‘Moriya’ is used by an unknown actor to deploy passive backdoors on public facing servers, facilitating the creation of a covert C&C communication channel through which they can be silently controlled. The victims are located in Africa, South and South-East Asia.

APT trends report Q1 2021

This report highlights significant events related to advanced persistent threat (APT) activity observed in Q1 2021. The summaries are based on our threat intelligence research and provide a representative snapshot of what we have published and discussed in greater detail in our private APT reports.

The leap of a Cycldek-related threat actor

The investigation described in this article started with one such file which caught our attention due to the various improvements it brought to this well-known infection vector.

Subscribe to our weekly e-mails

The hottest research right in your inbox